NCT00061321View on ClinicalTrials.gov

Daily Nevirapine to Prevent Mother to Infant Transmission of HIV

PHASE3CompletedINTERVENTIONAL

Enrollment

770

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

April 30, 2007

Study Completion Date

September 30, 2007

Conditions

HIV Infections

Interventions

DRUG

Nevirapine and mulitvitamins

Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum

Trial Locations (1)

Unknown

BJ Medical College, Pune

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00061321 - Daily Nevirapine to Prevent Mother to Infant Transmission of HIV | Biotech Hunter | Biotech Hunter